News: Biologics, Therapeutics and Devices

Jason McLellan has been named the recipient of a Research!America Advocacy Award for his work on COIVD-19 vaccines

Drug candidate developed by Everett Stone and his team is effective in mice with cancers of skin, bladder, blood and colon.

Every year, millions of people become sickened by RSV, and more than 100,000 die. New vaccines with a connection to UT Austin may help turn...

A biologist at UT Austin who played a key role in the development of COVID-19 and RSV vaccines has received honors for the far-reaching impact...

Alone, this target might not be strong enough to directly block infection, but it might be used to jump-start or boost an immune response.

Jason McLellan receives the NAS Award in Molecular Biology and the Norman Hackerman Award from the Welch Foundation.

A new University of Texas at Austin initiative will focus primarily on biologic research and development.

New findings could lead to a vaccine for one more respiratory virus.

An infectious disease researcher at The University of Texas at Austin has been named a finalist for a major national science award.

Jason McLellan and his team advance understanding of human metapneumovirus (hMPV) and human cytomegalovirus (HCMV), which can help them develop vaccines.